| Diagnosis | Sex: n (%) | Mean age (SD) | Immunomodulatory treatment | ||
| Male | Female | N (%) | Medication(s) (number of patients) | ||
| Non-diarrhea control (n = 48) | 24 (50) | 24 (50) | 58.7 (17.0) | 5 (10) | Betamethasone (1), methotrexate (1), methotrexate, prednisolone, and sulfasalazine (1), prednisolone (1), methotrexate and diclofenac (1) |
| Diarrhea control (n = 25) | 6 (24) | 19 (76) | 49.3 (18.2) | 0 (0) | N/A |
| LC active (n = 11) | 0 (0) | 11 (100) | 68.7 (9.3) | 1 (9) | Budesonide (1) |
| CC active (n = 21) | 3 (14) | 18 (86) | 60.3 (13.1) | 5 (24) | Budesonide (4), cyclosporine and prednisolone (1) |
| UC active (n = 19) | 13 (68) | 6 (32) | 50.1 (15.7) | 14 (74) | Azathioprine (1), mesalazine (11), mesalazine and methotrexate (1), olsalazine (1) |
| LC-HR (n = 9) | 0 (0) | 9 (100) | 57.0 (22.8) | 1 (11) | Budesonide (1) |
| CC-HR (n = 6) | 0 (0) | 6 (100) | 60.2 (9.0) | 2 (33) | Budesonide (1), budesonide and sulfasalazine (1) |
| UC remission (n = 19) | 13 (68) | 6 (32) | 56.0 (13.6) | 12 (63) | Balsalazide (1), mesalazine (4), olsalazine (4), sulfasalazine (3) |
| Diagnosis | Sex: n (%) | Mean age (SD) | Immunomodulatory treatment | ||
| Male | Female | N (%) | Medication(s) (number of patients) | ||
| Non-diarrhea control (n = 48) | 24 (50) | 24 (50) | 58.7 (17.0) | 5 (10) | Betamethasone (1), methotrexate (1), methotrexate, prednisolone, and sulfasalazine (1), prednisolone (1), methotrexate and diclofenac (1) |
| Diarrhea control (n = 25) | 6 (24) | 19 (76) | 49.3 (18.2) | 0 (0) | N/A |
| LC active (n = 11) | 0 (0) | 11 (100) | 68.7 (9.3) | 1 (9) | Budesonide (1) |
| CC active (n = 21) | 3 (14) | 18 (86) | 60.3 (13.1) | 5 (24) | Budesonide (4), cyclosporine and prednisolone (1) |
| UC active (n = 19) | 13 (68) | 6 (32) | 50.1 (15.7) | 14 (74) | Azathioprine (1), mesalazine (11), mesalazine and methotrexate (1), olsalazine (1) |
| LC-HR (n = 9) | 0 (0) | 9 (100) | 57.0 (22.8) | 1 (11) | Budesonide (1) |
| CC-HR (n = 6) | 0 (0) | 6 (100) | 60.2 (9.0) | 2 (33) | Budesonide (1), budesonide and sulfasalazine (1) |
| UC remission (n = 19) | 13 (68) | 6 (32) | 56.0 (13.6) | 12 (63) | Balsalazide (1), mesalazine (4), olsalazine (4), sulfasalazine (3) |
Samples from one patient with LC were included both when in active disease and when in HR and samples from one patient with active UC were included twice with an interval of approximately a year between biopsies being taken. Information about immunomodulatory treatment was unavailable for one control.
Abbreviations: CC, collagenous colitis; CC-HR, collagenous colitis in histological remission; LC, lymphocytic colitis; LC-HR, lymphocytic colitis in histological remission; UC, ulcerative colitis.
| Diagnosis | Sex: n (%) | Mean age (SD) | Immunomodulatory treatment | ||
| Male | Female | N (%) | Medication(s) (number of patients) | ||
| Non-diarrhea control (n = 48) | 24 (50) | 24 (50) | 58.7 (17.0) | 5 (10) | Betamethasone (1), methotrexate (1), methotrexate, prednisolone, and sulfasalazine (1), prednisolone (1), methotrexate and diclofenac (1) |
| Diarrhea control (n = 25) | 6 (24) | 19 (76) | 49.3 (18.2) | 0 (0) | N/A |
| LC active (n = 11) | 0 (0) | 11 (100) | 68.7 (9.3) | 1 (9) | Budesonide (1) |
| CC active (n = 21) | 3 (14) | 18 (86) | 60.3 (13.1) | 5 (24) | Budesonide (4), cyclosporine and prednisolone (1) |
| UC active (n = 19) | 13 (68) | 6 (32) | 50.1 (15.7) | 14 (74) | Azathioprine (1), mesalazine (11), mesalazine and methotrexate (1), olsalazine (1) |
| LC-HR (n = 9) | 0 (0) | 9 (100) | 57.0 (22.8) | 1 (11) | Budesonide (1) |
| CC-HR (n = 6) | 0 (0) | 6 (100) | 60.2 (9.0) | 2 (33) | Budesonide (1), budesonide and sulfasalazine (1) |
| UC remission (n = 19) | 13 (68) | 6 (32) | 56.0 (13.6) | 12 (63) | Balsalazide (1), mesalazine (4), olsalazine (4), sulfasalazine (3) |
| Diagnosis | Sex: n (%) | Mean age (SD) | Immunomodulatory treatment | ||
| Male | Female | N (%) | Medication(s) (number of patients) | ||
| Non-diarrhea control (n = 48) | 24 (50) | 24 (50) | 58.7 (17.0) | 5 (10) | Betamethasone (1), methotrexate (1), methotrexate, prednisolone, and sulfasalazine (1), prednisolone (1), methotrexate and diclofenac (1) |
| Diarrhea control (n = 25) | 6 (24) | 19 (76) | 49.3 (18.2) | 0 (0) | N/A |
| LC active (n = 11) | 0 (0) | 11 (100) | 68.7 (9.3) | 1 (9) | Budesonide (1) |
| CC active (n = 21) | 3 (14) | 18 (86) | 60.3 (13.1) | 5 (24) | Budesonide (4), cyclosporine and prednisolone (1) |
| UC active (n = 19) | 13 (68) | 6 (32) | 50.1 (15.7) | 14 (74) | Azathioprine (1), mesalazine (11), mesalazine and methotrexate (1), olsalazine (1) |
| LC-HR (n = 9) | 0 (0) | 9 (100) | 57.0 (22.8) | 1 (11) | Budesonide (1) |
| CC-HR (n = 6) | 0 (0) | 6 (100) | 60.2 (9.0) | 2 (33) | Budesonide (1), budesonide and sulfasalazine (1) |
| UC remission (n = 19) | 13 (68) | 6 (32) | 56.0 (13.6) | 12 (63) | Balsalazide (1), mesalazine (4), olsalazine (4), sulfasalazine (3) |
Samples from one patient with LC were included both when in active disease and when in HR and samples from one patient with active UC were included twice with an interval of approximately a year between biopsies being taken. Information about immunomodulatory treatment was unavailable for one control.
Abbreviations: CC, collagenous colitis; CC-HR, collagenous colitis in histological remission; LC, lymphocytic colitis; LC-HR, lymphocytic colitis in histological remission; UC, ulcerative colitis.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
